Is retatrutide FDA-approved, and when could it be available?

Retatrutide has finished its main phase 3 obesity trials but is not FDA-approved, and Lilly says it plans to apply in early 2027.

Basics7 min read

Key takeaway

Retatrutide is not FDA-approved for any use as of November 17, 2026. Four phase 3 TRIUMPH trials are complete, and TRIUMPH-1 and TRIUMPH-2 have been published in peer-reviewed journals. In July 2026, Lilly said it plans to submit retatrutide to FDA in the first quarter of 2027. Approval would come only after FDA review. Until then, FDA says retatrutide cannot be used in compounding, and Lilly says it cannot be legally sold or marketed for human use.

At a glance

Article typeBasics
Main guideRetatrutide: complete guide
Regulatory statusIn clinical trials“It's in Phase III development under Lilly's TRIUMPH program” (Retatrutide: complete guide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited3 in this article · 13 across 11 articles on Retatrutide
ProductRetatrutide product page

Retatrutide FDA approval has not happened yet. The drug has finished its main phase 3 obesity trials, and Eli Lilly has said when it plans to apply. This guide covers what the trials reported, what Lilly has said about timing, and what "not FDA-approved" means in practice, using the trial papers, ClinicalTrials.gov and FDA and Lilly statements checked on November 17, 2026.

Quick answer: No, retatrutide is not FDA-approved. Lilly plans to apply in early 2027, and FDA must review the application before any approval. Today the only lawful ways for a person to receive it are a Lilly clinical trial or Lilly's physician-requested expanded access program. Research-grade retatrutide is a laboratory reagent for laboratory research use only, not for human or veterinary use, and it is not a substitute for an approved medicine.

What is retatrutide?

Retatrutide, also known by Lilly's code LY3437943, is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon (Jastreboff et al., 2023). Lilly develops it and describes it as "an investigational molecule that cannot be legally sold or marketed for human use" (Lilly, July 23, 2026). For the research background, see our retatrutide research guide and our article on its triple-agonist mechanism.

What did the phase 2 trial show?

The phase 2 trial, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity, or with overweight plus a weight-related condition. It was randomized, double-blind and placebo-controlled, and ran for 48 weeks (NCT04881760).

The primary end point was the percentage change in body weight from baseline to 24 weeks. The authors reported mean reductions of 7.2% to 17.5% across the retatrutide groups, against 1.6% with placebo. The most common adverse events were gastrointestinal, related to dose, and mostly mild to moderate. Heart rate rose in a dose-dependent way, peaked at 24 weeks and declined after that. Our phase 2 trial review goes through the design in detail.

What is the TRIUMPH phase 3 program?

TRIUMPH is Lilly's phase 3 program for retatrutide in obesity and related conditions. Table 1 lists the TRIUMPH trials registered on ClinicalTrials.gov and their status on November 17, 2026. Status changes, so check each record for the latest.

Table 1

TRIUMPH phase 3 trials on ClinicalTrials.gov (status as of November 17, 2026)

Trial Registry ID Population studied Status
TRIUMPH-1 NCT05929066 Obesity or overweight Completed
TRIUMPH-2 NCT05929079 Obesity or overweight with type 2 diabetes Completed
TRIUMPH-3 NCT05882045 Obesity with cardiovascular disease Completed
TRIUMPH-4 NCT05931367 Obesity or overweight with knee osteoarthritis Completed
TRIUMPH-5 NCT06662383 Obesity, compared with tirzepatide Active, not recruiting
TRIUMPH-6 NCT06859268 Maintenance of weight reduction Active, not recruiting
TRIUMPH-7 NCT07035093 Obesity or overweight with chronic low back pain Active, not recruiting
TRIUMPH-8 NCT07232719 Obesity or overweight Active, not recruiting
TRIUMPH-9 NCT07357415 Obesity or overweight without type 2 diabetes Active, not recruiting
TRIUMPH-Outcomes NCT06383390 Cardiovascular and kidney outcomes Active, not recruiting

What results have been published from phase 3?

TRIUMPH-1 and TRIUMPH-2 have been published in full. Both used body-weight change at 80 weeks as the primary end point.

  • TRIUMPH-1 (New England Journal of Medicine, 2026) randomized 2,339 adults with obesity and without diabetes. Mean body-weight change across the three retatrutide groups ranged from a 17.6% to a 25.0% reduction, against 3.9% with placebo (Jastreboff et al., 2026). The trial also measured knee pain and sleep apnea in subgroups. The most common adverse events were gastrointestinal.
  • TRIUMPH-2 (The Lancet, 2026) randomized 1,152 adults with type 2 diabetes and a BMI of 27 or higher. Mean reductions ranged from 11.9% to 18.8% across the retatrutide groups, against 5.1% with placebo (Bellido et al., 2026). Gastrointestinal events were again the most common.

Lilly has also reported topline results by press release:

  • TRIUMPH-4 (December 11, 2025): 445 adults with obesity or overweight and knee osteoarthritis, over 68 weeks. Lilly said the trial met its co-primary end points for body weight and knee pain, with a 28.7% mean weight reduction in the highest-dose group against 2.1% with placebo (Lilly).
  • TRIUMPH-3 (July 23, 2026): 1,949 adults with severe obesity and established cardiovascular disease, over 80 weeks. Lilly said the trial met its primary end point, with a 22.6% mean reduction in the highest-dose group against 3.2% with placebo.

The two sets of numbers are not directly comparable. Lilly's releases lead with what it calls the efficacy estimand, which estimates the effect "had all randomized participants remained on study intervention." The journal papers lead with the treatment-regimen estimand, which counts everyone regardless of adherence and gives smaller figures. Lilly also reported that discontinuations due to adverse events were higher with retatrutide than with placebo.

When will retatrutide be available?

Not before FDA approves it, and Lilly has not yet applied. On July 23, 2026, Lilly said it "is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval." Lilly's third-quarter results release of October 29, 2026 did not report a submission, and we found no later announcement as of November 17, 2026.

After a submission, FDA's published goal is to act within 10 months under standard review, or 6 months under priority review (FDA). FDA decides whether to approve at the end of its review. Any date beyond that is a forecast, not a fact.

Before approval, a person can receive retatrutide only through Lilly. In May 2026, Lilly said retatrutide "is legally available only to participants in Lilly's clinical trials" (Lilly, May 21, 2026). Since June 2026, Lilly has also listed a pre-approval expanded access program. It is single-patient, requested by a treating physician, and limited to adults with severe obesity who meet strict criteria and cannot join a trial (NCT07629401). FDA describes expanded access as a potential pathway for patients with serious conditions when no comparable or satisfactory alternative exists (FDA).

What does "not FDA-approved" mean today?

  • No compounding. FDA states that "retatrutide and cagrilintide cannot be used in compounding under federal law," because neither is a component of an FDA-approved drug and neither has been found safe and effective for any condition (FDA).
  • No sale for human use. FDA has sent warning letters to telehealth companies marketing retatrutide, to ingredient distributors selling it to compounders, and to outsourcing facilities repackaging it.
  • No research-label workaround. FDA has warned companies that sold retatrutide and other GLP-1 products falsely labeled for research purposes while selling them "directly to consumers for human use with dosing instructions." In a March 31, 2026 warning letter, FDA said a seller's retatrutide products were "intended to be drugs for human use" despite "laboratory research purposes only" labeling.

Lilly has said the same from its side. In August 2026 it called on platforms, payment companies and regulators to shut down what it called an illegal retatrutide black market (Lilly, August 12, 2026).

Why isn't research-grade retatrutide a substitute?

An approved medicine has been through FDA review of its safety, effectiveness, manufacturing and labeling, and it reaches a patient through a prescriber. The trial results above come from Lilly's investigational product, given under clinical trial oversight. None of that carries over to material sold for laboratory work.

Research-grade retatrutide is a laboratory reagent. It is for laboratory research use only, not for human or veterinary use, and it is not an alternative to an approved medicine or a clinical trial. FDA describes research-labeled GLP-1 products sold for human use as "of unknown quality" and says they "may be harmful." For what the research-use label covers, see what research use only means.

Frequently asked questions about retatrutide approval

Is retatrutide FDA-approved?

No. As of November 17, 2026, it is an investigational drug with no FDA approval for any use.

When will retatrutide be available?

Lilly plans to submit it to FDA in the first quarter of 2027. Availability depends on FDA's review and decision after that.

Can a pharmacy compound retatrutide?

No. FDA states that retatrutide cannot be used in compounding under federal law.

Is research-grade retatrutide legal to use in people?

No. Research-grade material is for laboratory research use only, not for human or veterinary use. FDA has acted against sellers who market research-labeled retatrutide for human use.

What to know now

  • Status: not FDA-approved as of November 17, 2026.
  • Phase 2: primary end point met at 24 weeks (NEJM, 2023).
  • Phase 3: TRIUMPH-1 to TRIUMPH-4 complete; TRIUMPH-1 and TRIUMPH-2 published in 2026.
  • Filing: Lilly plans to submit in the first quarter of 2027.
  • Access now: Lilly trials or physician-requested expanded access only.
  • Research grade: a laboratory reagent, not for human or veterinary use, and not a substitute.

What we're watching

Whether Lilly submits on its stated timeline, what kind of review FDA grants, a peer-reviewed paper for TRIUMPH-3, and results from TRIUMPH-5, which compares retatrutide with tirzepatide.

Also in the library

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Jastreboff 2023, New England Journal of Medicine; Jastreboff 2026, New England Journal of Medicine; Bellido 2026, The Lancet; ClinicalTrials.gov. A study of LY3437943 in participants who have obesity or are overweight (NCT04881760). https://clinicaltrials.gov/study/NCT04881760, A study of LY3437943 in participants who have obesity or are overweight; ClinicalTrials.gov. TRIUMPH-1 (NCT05929066). https://clinicaltrials.gov/study/NCT05929066, TRIUMPH-1; ClinicalTrials.gov. TRIUMPH-2 (NCT05929079). https://clinicaltrials.gov/study/NCT05929079, TRIUMPH-2; ClinicalTrials.gov. TRIUMPH-3 (NCT05882045). https://clinicaltrials.gov/study/NCT05882045, TRIUMPH-3; ClinicalTrials.gov. TRIUMPH-4 (NCT05931367). https://clinicaltrials.gov/study/NCT05931367, TRIUMPH-4; ClinicalTrials.gov. Pre-approval expanded access of retatrutide (LY3437943) (NCT07629401). https://clinicaltrials.gov/study/NCT07629401, Pre-approval expanded access of retatrutide (LY3437943); Eli Lilly and Company 2025; Eli Lilly and Company 2026; Eli Lilly and Company 2026; Eli Lilly and Company 2026; Eli Lilly and Company 2026, Lilly reports third-quarter 2026 financial results; U.S. Food and Drug Administration 2026, FDA's concerns with unapproved GLP-1 drugs used for weight loss; U.S. Food and Drug Administration 2026, Warning letter: Prime Sciences, MARCS-CMS 721805; U.S. Food and Drug Administration. Priority review . https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review, Priority review; U.S. Food and Drug Administration 2026, Expanded access. All 18 citations

Back to the research library

References

  1. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: A phase 2 trial. New England Journal of Medicine, 389(6), 514-526. https://doi.org/10.1056/NEJMoa2301972
  2. Jastreboff, A. M., Kaplan, L. M., Davies, M. J., et al. (2026). Retatrutide, a triple hormone receptor agonist, for treatment of obesity. New England Journal of Medicine, 395(18), 1781-1793. https://doi.org/10.1056/NEJMoa2604169
  3. Bellido, V., le Roux, C. W., Ekinci, E. I., et al. (2026). Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet, 408(10563), 1455-1472. https://doi.org/10.1016/S0140-6736(26)01861-1
  4. ClinicalTrials.gov. A study of LY3437943 in participants who have obesity or are overweight (NCT04881760). https://clinicaltrials.gov/study/NCT04881760
  5. ClinicalTrials.gov. TRIUMPH-1 (NCT05929066). https://clinicaltrials.gov/study/NCT05929066
  6. ClinicalTrials.gov. TRIUMPH-2 (NCT05929079). https://clinicaltrials.gov/study/NCT05929079
  7. ClinicalTrials.gov. TRIUMPH-3 (NCT05882045). https://clinicaltrials.gov/study/NCT05882045
  8. ClinicalTrials.gov. TRIUMPH-4 (NCT05931367). https://clinicaltrials.gov/study/NCT05931367
  9. ClinicalTrials.gov. Pre-approval expanded access of retatrutide (LY3437943) (NCT07629401). https://clinicaltrials.gov/study/NCT07629401
  10. Eli Lilly and Company. (2025, December 11). Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial [Press release]. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html
  11. Eli Lilly and Company. (2026, May 21). Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial [Press release]. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
  12. Eli Lilly and Company. (2026, July 23). Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C [Press release]. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html
  13. Eli Lilly and Company. (2026, August 12). Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market [Press release]. https://www.prnewswire.com/news-releases/lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal-retatrutide-black-market-302849551.html
  14. Eli Lilly and Company. (2026, October 29). Lilly reports third-quarter 2026 financial results (Form 8-K, Exhibit 99). https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000104/q326lillysalesandearningsp.htm
  15. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  16. U.S. Food and Drug Administration. (2026, March 31). Warning letter: Prime Sciences, MARCS-CMS 721805. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026
  17. U.S. Food and Drug Administration. Priority review. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review
  18. U.S. Food and Drug Administration. (2026). Expanded access (content current as of October 22, 2026). https://www.fda.gov/news-events/public-health-focus/expanded-access